Evidence map›Paper›PMID 30104904›Full record

ReviewInternational journal of women's health2018

Current treatment options for postmenopausal vaginal atrophy.

Iuliia Naumova, Camil Castelo-Branco

Registry-linked trialOpen access · goldAbstract readReview
In one paragraph

Review in International journal of women's health, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06925139 (Efficacy of Non-Ablative Radiofrequency on Vaginal and Sexual Health in Postmenopausal Women), which is not on this map. Cited by 57 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
57citing papers in PubMed, 3 pooled it
8.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06925139 nacompletednot on this mapstarted 2024, after this paper: background citation

Efficacy of Non-Ablative Radiofrequency on Vaginal and Sexual Health in Postmenopausal Women: a Randomized Clinical Trial

TypeinterventionalSponsorUniversity of Castilla-La ManchaRan2024 to 2024Enrolled62ConditionsGenitourinary Syndrome of Menopause, Vaginal Health, Sexual DysfunctionArmsNon-ablative monopolar radiofrequency treatment
3 · Its place in the literature

Who cites it

57 citing papers in PubMed, 3 syntheses or guidelines pooled it, 135 citations in OpenAlex.

  1. Pooled it
  2. Guideline
  3. Pooled it
  4. Efficacy and Safety of COMedicina (Kaunas, Lithuania) · 2026
    Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Multifaceted Impact of COHealthcare (Basel, Switzerland) · 2024
    Article
  20. Understanding the Benefits of COMedicina (Kaunas, Lithuania) · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 2 countries.

Iuliia NaumovaDepartment of Obstetrics and Gynecology, Faculty of General Medicine Saratov State Medical University named after V.I. Razumovsky, Saratov, Russia.
Camil Castelo-BrancoInstitute Clinic of Gynecology, Obstetrics and Neonatology, Faculty of Medicine-University of Barcelona, Hospital Clinic-August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain, castelobranco@ub.edu.
Hospital Clínic de Barcelona · ESSaratov State Medical University · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Vulvovaginal atrophy (VVA) is a silent epidemic that affects up to 50%-60% of postmenopausal women who are suffering in silence from this condition. Hormonal changes, especially hypoestrogenism inherent in menopause, are characterized by a variety of symptoms. More than half of menopausal women are concerned about the symptoms of VVA, such as dryness, burning, itching, vaginal discomfort, pain and burning when urinating, dyspareunia, and spotting during intercourse. All these manifestations significantly reduce the quality of life and cause discomfort in the sexual sphere. However, according to research, only 25% of patients with the symptoms of VVA receive adequate therapy. This is probably due to the lack of coverage of this problem in the society and the insufficiently active position of specialists in the field of women's health regarding the detection of symptoms of VVA. Many patients are embarrassed to discuss intimate complaints with a specialist, which makes it difficult to verify the diagnosis in 75% of cases, and some patients regard the symptoms of VVA as manifestations of the natural aging process and do not seek help. Modern medicine has in the arsenal various options for treating this pathological condition, including systemic and topical hormone replacement therapy, the use of selective estrogen receptor modulators, vaginal dehydroepiandrosterone, use of lubricants and moisturizers, as well as non-drug therapies. Timely diagnosis and adequately selected therapy for the main symptoms of VVA lead to restoration and maintenance of the vaginal function and vaginal health.

Indexed as

dyspareuniahormonal replacement therapylocal estrogenmenopauseselective estrogen receptor modulatorvaginal dehydroepiandrosteronevaginal drynessvulvovaginal atrophy

Identifiers

PMID30104904
PMCPMC6074805
OpenAlexW2883543061

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.